Last updated: February 27, 2026
What is the Drug Corresponding to NDC 10572-0012?
The NDC 10572-0012 refers to Ruxolitinib, marketed as Jakafi by Incyte. It is a Janus kinase (JAK) inhibitor approved for treating myelofibrosis, polycythemia vera, and graft-versus-host disease.
Market Landscape
Therapeutic Area and Demand Drivers
- Indications: Myelofibrosis, polycythemia vera, graft-versus-host disease.
- Market Size: The global myelofibrosis treatment market was valued at approximately $1.2 billion in 2022, projected to grow at a CAGR of around 7% until 2030 (Grand View Research, 2023).
Key Competitors
- Fedratinib (Inrebic) by Spectrum Pharmaceuticals
- Momelotinib (in development stages)
- Hydroxyurea (off-label use for polycythemia vera)
Market Trends
- Increasing diagnosis rates of myeloproliferative neoplasms.
- Growing adoption of targeted therapies over chemotherapy.
- Expanding indications, including for the prevention of graft-versus-host disease before FDA approval for this use in 2019.
Current Pricing Dynamics
Pricing Overview
- List Price: Ruxolitinib's wholesale acquisition cost (WAC) is approximately $11,400 per month for a 60 mg twice-daily dose, depending on individual dose adjustments (Medicare Part D data, 2023).
- Average Wholesale Price (AWP): Around $14,000 per month.
- Net Prices: Payers and insurers may negotiate discounts, often reducing the effective patient cost by 20-40%.
Reimbursement Landscape
- Managed through formulary inclusion and prior authorization.
- Coverage reflects the drug’s status as a first-line therapy for certain myeloproliferative neoplasms.
- Special access via patient assistance programs by Incyte.
Price Projections
Short-term (1-2 Years)
- Stable Pricing: No significant price reduction forecasted due to lack of generics; patent protections are active until 2029.
- Market Expansion: Anticipated increase in volume driven by broader indication approvals and increased diagnosis rates.
Medium-term (3-5 Years)
- Potential for Price Adjustments: Entry of biosimilars or generics could pressure prices downward. However, currently, no biosimilar pathway exists for JAK inhibitors.
- Pricing Trends: Expect a 2-3% annual increase in net prices aligned with inflation and market conditions, barring policy changes.
Long-term (5+ Years)
- Patent Expiry Effects: Generally, patent expiration around 2029 could introduce generics, potentially halving prices or more.
- Market Competition: Biologic competitors or new agents with superior efficacy could impact pricing and market share.
Regulatory and Market Risks Impacting Pricing
- Patent Litigation: Ongoing legal defenses may extend exclusivity.
- Policy Changes: Price regulation initiatives in the U.S. could impose caps or mandates for price negotiations.
- Market Penetration: Adoption rates in emerging markets will influence global revenue but typically at lower price points.
Strategic Considerations
- Manufacturers should monitor biosimilar development channels.
- Payers may negotiate for volume discounts or impose formulary restrictions.
- R&D investments in next-generation JAK inhibitors or combination therapies could affect future market dynamics.
Key Takeaways
- Ruxolitinib (NDC 10572-0012) maintains a high retail price with limited near-term downward pressure.
- The market size is expected to grow annually at approximately 7% driven by clinical adoption.
- Patent protection until 2029 suggests stable pricing through at least the next five years.
- Entry of generics around 2029 could significantly reduce prices, impacting revenues.
- Market expansion into new indications and regions supports continued revenue growth despite potential price erosion.
FAQs
1. What factors influence Ruxolitinib’s price in the current market?
Pricing is influenced by manufacturing costs, market demand, patent status, negotiated discounts, and payer policies.
2. When can generics or biosimilars be expected to enter the market?
Patent expiry is projected around 2029, with biosimilar entry contingent on regulatory approval and market acceptance.
3. How does the drug’s pricing compare globally?
Prices vary significantly; in Europe, prices are typically 20-30% lower due to cost regulations, while in emerging markets, prices are often substantially lower.
4. Are there upcoming regulatory changes that could affect pricing?
Legislative proposals for drug price regulation exist but have not yet been enacted into law. Future policy shifts could alter the pricing landscape.
5. How does market competition affect future pricing?
Emerging therapies and biosimilars will likely exert downward pressure, especially post-patent expiration, reducing the drug’s market share and revenues.
References
- Grand View Research. (2023). Myelofibrosis Treatment Market Size, Share & Trends Analysis Report.
- MedPage Today. (2023). Incyte’s Jakafi pricing.
- U.S. Food & Drug Administration. (2019). FDA Approval of Jakafi for Graft-versus-Host Disease.
- Medicare Part D Data. (2023). Average wholesale prices for Ruxolitinib.
- Incyte Corporation. (2023). Financial disclosures and patent filings.
